Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Kidney Neoplasms

• Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
• Advanced Diffusion Imaging in Renal Cancer Patients
• Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
• Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
• HTL0039732 in Participants With Advanced Solid Tumours
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
• 64Cu-GRIP B in Patients With Advanced Genitourinary Malignancies
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
• A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
• NSAID Use After Robotic Partial Nephrectomy
• Preop Laxatives in Robotic Urologic Surgery
• Measuring Oncological Value of Exercise and Statin
• A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors
• Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
• A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
• Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
• A Pilot Study of the Immunomodulatory Agent Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
• Pebolizumab Plus Lumvaritinib in Stage III-IV RCC
• Tirelizumab Plus Lumvaritinib in Stage III-IV RCC
• A Phase 2 Study of 6MW3211 in Patients With Advanced Clear Cell Renal Cancer
• Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
• Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
• Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
• CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Chemotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
• Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• Sacituzumab Govitecan Plus EV in Metastatic UC
• the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
• Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
• A Study of PY314 in Subjects With Advanced Solid Tumors
• Neoadjuvant PD-1 Monoclonal Antibody in Locally Advanced Upper Tract Urothelial Carcinoma
• Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma
• Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
• Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
• Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
• Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
• Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
• Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
• CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
• Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
• Effect of Papaverine on Renal Artery Blood Flow Volume
• Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
• PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46
• Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study
• SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
• Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
• Efficacy and Safety of UGN-101 in Recurrent Patients
• Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
• MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
• Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
• Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
• Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors
• Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
• 9-ING-41 in Patients With Advanced Cancers
• A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
• Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma
• Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
• Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
• Effects of Anesthesia on Immunity in Cancer
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
• Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
• Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
• Study of Nivolumab for Advanced Cancers in India
• Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
• Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
• Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
• Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
• Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
• Savolitinib vs. Sunitinib in MET-driven PRCC.
• Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
• Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
• SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
• Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
• Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
• Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
• A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
• Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
• A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
• NeoVax Plus Ipilimumab in Renal Cell Carcinoma
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
• Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
• Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
• Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
• Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
• A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
• Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
• Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
• A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
• Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
• Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
• Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
• A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
• Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
• A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
• Bevacizumab in Metastatic Renal Cancer
• Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC)
• A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
• Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
• Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
• A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
• PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
• Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
• Survivorship Promotion In Reducing IGF-1 Trial
• Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
• A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
• Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
• A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
• Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
• [18F]Fluciclatide PET Imaging of Pazopanib Response
• Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer
• Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
• Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
• A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy
• A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
• Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
• Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
• REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
• Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer
• Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
• Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
• Imaging Studies of Kidney Cancer Using 18F-VM4-037
• Interleukin-2 in Metastatic Kidney Cancer
• Cabozantinib for Advanced Urothelial Cancer
• Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
• Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
• [18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
• Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
• Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
• Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
• Vascular Targeted Photodynamic Therapy T1a Renal Tumours
• Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
• AMG 172 First in Human Study in Patients With Kidney Cancer
• Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
• Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
• BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
• Rotating Pazopanib and Everolimus to Avoid Resistance
• Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
• Vandetanib to Treat Advanced Kidney Cancer
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
• Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
• A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
• Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
• Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
• Cancer in Patients With Gabapentin (GPRD)
• Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
• Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
• CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
• Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
• Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
• Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
• Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
• Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
• Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
• Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
• Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
• Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
• Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
• A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
• Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
• Sunitinib in Metastatic Renal Cancer
• Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
• Dose Dense MVAC for Muscle Invasive Bladder Cancer
• Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
• Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
• Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
• Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
• 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
• A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
• Acceptability of Less Harmful Alternatives to Cigarettes
• Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
• Sunitinib Malate in Treating Patients With Kidney Cancer
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
• Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
• Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
• Study In Patients With Kidney Cancer Treated With Sutent
• Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
• Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
• Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
• Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
• Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
• Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
• Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
• Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
• Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
• Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
• Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
• Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
• Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
• Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
• Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• Natural Killer Cells and Bortezomib to Treat Cancer
• Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
• Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
• Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
• Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
• A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
• Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
• Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
• Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
• Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
• MT2004-30: Tomotherapy for Solid Tumors
• Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
• Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
• Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
• Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
• Phase II Study of Vandetanib in Individuals With Kidney Cancer
• LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
• Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
• Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
• Bupropion in Helping Adults Stop Smoking
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
• Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
• Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
• Zoledronate With Atorvastatin in Renal Cell Carcinoma
• Talabostat in Treating Patients With Metastatic Kidney Cancer
• Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
• Pazopanib in Treating Patients With Metastatic Urothelial Cancer
• OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
• Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
• Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
• Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
• Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
• High-dose Bevacizumab in Advanced Renal Carcinoma Patients
• Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
• A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
• Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
• Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
• Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
• Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
• Perifosine + Sunitinib Malate for Patients With Advanced Cancers
• Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
• A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
• A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
• Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
• Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
• Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
• Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
• Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
• Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
• Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
• Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
• Ixabepilone in Treating Young Patients With Refractory Solid Tumors
• Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
• Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
• Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
• Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
• Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
• Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
• Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
• Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
• Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
• Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery
• Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
• Bortezomib in Treating Patients With Metastatic Kidney Cancer
• Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
• Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
• Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
• A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
• Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
• Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
• OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
• Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
• Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
• Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
• Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
• Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
• Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
• Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
• PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
• Vaccine Treatment of Kidney Cancer
• Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
• S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
• Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
• Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
• Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
• 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
• Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
• Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
• S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
• Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
• Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
• Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
• A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
• S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
• ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
• Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
• Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
• Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
• Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
• Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
• S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
• Erlotinib in Treating Patients With Advanced Kidney Cancer
• Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
• Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
• BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
• ABT-751 in Treating Young Patients With Refractory Solid Tumors
• EPO906 Therapy in Patients With Advanced Kidney Cancer
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
• UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
• Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
• Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
• Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
• Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
• Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
• PS-341 in Treating Patients With Metastatic Kidney Cancer
• Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney
• Chemotherapy in Treating Patients With Metastatic Kidney Cancer
• Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
• SU006668 in Treating Patients With Advanced Solid Tumors
• S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
• Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
• Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
• Caspofungin Acetate in Treating Children With Fever and Neutropenia
• Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
• Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
• PS-341 in Treating Patients With Metastatic Kidney Cancer
• Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
• ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
• S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
• ZD 1839 in Treating Patients With Metastatic Kidney Cancer
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
• Chemotherapy in Treating Patients With Advanced Kidney Cancer
• Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
• Arsenic Trioxide in Treating Patients With Urothelial Cancer
• Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
• SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
• R115777 in Treating Patients With Advanced Bladder Cancer
• SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
• Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
• Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
• Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
• Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
• AE-941 in Treating Patients With Metastatic Kidney Cancer
• Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
• Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
• Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
• Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
• Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
• Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
• Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
• Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
• Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
• Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
• Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
• Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
• Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
• Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
• Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
• Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
• Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
• Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor
• Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
• Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
• High-dose ICE With Amifostine
• Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
• Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
• Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
• Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
• Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer
• Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
• 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
• Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
• Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
• Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
• Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
• Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
• Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
• Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
• Chemotherapy in Treating Patients With Solid Tumors
• Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
• Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
• Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
• Biological Therapy in Treating Patients With Metastatic Cancer
• Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
• Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
• Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
• Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
• Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
• A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
• A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833